Table 3. Prevalence of Antibiotic Resistance in the Pseudomonas aeruginosa Isolates of Iranian Patientsa.
| Criteria (No. of Isolates) | Prevalence of Antibiotic Resistance (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nor | AMP | IMP | Gen | CIP | Cef | Cefo | Cotr | Pol B | Merop | AMK | Van | Cefta | Azt | |
| Gender | ||||||||||||||
| Male (3) | 2 (66.6) | 3 (100) | 3 (100) | 2 (66.6) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 2 (66.6) | 1 (33.3) | 1 (33.3) | 2 (66.6) | |||
| Female (5) | 3 (60) | 4 (80) | 4 (80) | 3 (60) | 2 (40) | 2 (40) | 2 (40) | 1 (20) | 3 (60) | 2 (40) | 2 (40) | 3 (60) | ||
| Age, y | ||||||||||||||
| < 10 (3) | 2 (66.6) | |||||||||||||
| 10 - 25 (1) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | ||||||||||
| 40 - 55 (1) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | |||
| > 55 (3) | 3 (100) | 3 (100) | 1 (33.3) | 2 (66.6) | 2 (66.6) | 2 (66.6) | 2 (66.6) | 2 (66.6) | 1 (33.3) | 3 (100) | 2 (66.6) | 2 (66.6) | 3 (100) | |
| Total (8) | 5 (62.5) | 7 (87.5) | 1 (12.5) | 5 (62.5) | 3 (37.5) | 3 (37.5) | 3 (37.5) | 3 (37.5) | 1 (12.5) | 5 (62.5) | 3 (37.5) | 3 (37.5) | 5 (62.5) | |
aAbbreviations: AMK, amikacin (30 u/disk); AMP, ampicillin (10 u/disk); Azt, aztreonam (30 µg/disk); Cef, cefipime (30 µg/disk); Cefo, cefoperazone (30 µg/disk); Cefta, ceftazidime (30 µg/disk); CIP, ciprofloxacin (5 µg/disk); Cotr, cotrimoxazole (30 µg/disk); Gen, gentamycin (10 µg/disk); IMP, imipenem (30 u/disk); Merop, meropenem (10 µg/disk); Nor, norfloxacin (30 µg/disk); Pol B, polymyxin B (300 U/disk); Van, vancomycine (5 µg/disk).